AI Summary Imjudo (tremelimumab) is a CTLA-4 inhibitor immunotherapy given with Imfinzi as part of the STRIDE regimen for unresectable hepatocellular carcinoma.
Medically reviewed.
Imjudo (tremelimumab) is a prescription immunotherapy used together with Imfinzi (durvalumab) to treat unresectable hepatocellular carcinoma (HCC), a liver cancer that cannot be removed with surgery. It is a CTLA-4 inhibitor, a medicine that helps activate the immune cells that fight cancer. Imjudo is commonly given as part of the STRIDE regimen for advanced liver cancer. Treatment decisions should always be individualized and guided by a healthcare professional.
This page covers Imjudo's role in liver cancer care: how it works, who may be eligible, how it is given, benefits, side effects, and monitoring. You can also connect with a liver specialist near you for personalized guidance on whether Imjudo fits your care plan.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
ABOUT IMJUDO TREATMENT
Imjudo is a prescription medicine that contains tremelimumab. It belongs to a class of medications called CTLA-4 inhibitors, a type of immunotherapy. Immunotherapy helps the body's immune system fight cancer.
In liver cancer, Imjudo is used with Imfinzi (durvalumab) to treat unresectable hepatocellular carcinoma (HCC). "Unresectable" means the cancer cannot be removed with surgery.
Imjudo is commonly given as part of the STRIDE regimen for advanced liver cancer. It is a systemic treatment, which means it works throughout the body.
A healthcare professional prepares and gives Imjudo. Your care team also tracks your response to treatment regularly, for example with Liver Function Tests (LFTs).
WHO IMJUDO MAY BE SUITABLE FOR
Your healthcare provider may prescribe Imjudo if you have unresectable hepatocellular carcinoma, you are eligible for combination immunotherapy, and your provider recommends the STRIDE regimen. It is also considered when your cancer needs systemic treatment and you may benefit from a stronger immune response against the cancer.
Every patient's health profile is different, so there is no one-size-fits-all answer. Treatment decisions are individualized and should be made by a qualified healthcare professional after a full assessment of your liver condition and treatment goals.
ELIGIBILITY OVERVIEW
Imjudo may be considered for adults with the following conditions or treatment goals:
Before recommending Imjudo, your healthcare provider looks at whether it fits your situation, including:
HOW IMJUDO CAN HELP
Immune cells called T-cells help the body find and attack cancer. Cancer can hold these cells back through "checkpoints," which act like brakes on the immune response. Imjudo blocks one of these checkpoints, the CTLA-4 pathway.
With CTLA-4 blocked, T-cells become more active, and the immune system is better able to recognize cancer cells. Imjudo works together with Imfinzi, which blocks a different checkpoint, PD-L1.
Imjudo is used as a systemic treatment, not on its own. Your care team gives it as part of the STRIDE regimen and checks your response and any side effects at regular visits.
LIVER CANCER CARE
Imjudo enhances the body's immune response against cancer. It promotes the activation of immune cells that take part in anti-cancer responses, and it strengthens T-cell activity. This gives the immune system a better chance to recognize and respond to cancer cells in the liver.
Cancer can hold T-cells back through checkpoints, which act like brakes on the immune response. Imjudo blocks one of them, the CTLA-4 pathway. With that brake released, T-cells become more active and can recognize cancer cells more easily.
Imjudo is designed for use with Imfinzi, which blocks a different checkpoint, PD-L1. The two medicines work together as part of the STRIDE regimen. Imjudo is given first as a single priming dose, and treatment then continues with Imfinzi.
Imjudo is an approved option for unresectable hepatocellular carcinoma, a liver cancer that surgery cannot remove. It is a systemic treatment, so it works throughout the body. Your care team decides whether it fits your situation and checks your response and any side effects at regular visits.
Imjudo blocks CTLA-4 to boost the immune response against liver cancer and is used with Imfinzi. It should only be started and monitored under the guidance of a qualified healthcare professional.
TREATMENT PROCESS
A healthcare professional prepares and gives Imjudo. You do not prepare it yourself.
For unresectable hepatocellular carcinoma, the approved STRIDE regimen uses a single 300 mg intravenous (IV) dose of Imjudo on Day 1, together with Imfinzi 1,500 mg IV. Your healthcare provider determines the right plan for you.
Imjudo is given by IV infusion over about 60 minutes. When both medicines are given on the same day, Imjudo is infused before Imfinzi.
In most STRIDE treatment plans, Imjudo is a single priming dose. After that, treatment continues with Imfinzi 1,500 mg IV every 4 weeks until the disease progresses or side effects become unacceptable. Overall treatment length depends on your response, how well you tolerate it, and the course of your disease. It may last months to years.
Your healthcare team stores and handles Imjudo. You do not need to store it at home.
Regular monitoring for immune-related side effects and for how well treatment is working is required. Keep all scheduled oncology visits. Report any side effects or unusual symptoms to your care team right away.
BENEFITS AND SAFETY
Imjudo (tremelimumab) is an approved option for unresectable hepatocellular carcinoma. By blocking CTLA-4, it strengthens T-cell activity and enhances the body's immune response against cancer. It is designed for use with Imfinzi as part of the STRIDE regimen. Benefits and side effects vary from person to person. Imjudo is not a stand-alone treatment, and your care team will monitor you throughout therapy.
As with any medication, Imjudo may cause side effects. Because it activates the immune system, it can sometimes cause immune-related inflammation in organs such as the liver, lungs, intestines, or endocrine glands. Your healthcare provider will check for these effects at regular visits and decide whether treatment should continue.
BENEFITS
Imjudo enhances the body's immune response against cancer by strengthening T-cell activity. T-cells are the immune cells that help find and attack cancer, so more active T-cells can help the body respond to tumor cells in the liver.
Imjudo blocks the CTLA-4 pathway, one of the checkpoints that can slow the immune response. Blocking it helps T-cells recognize cancer cells and respond to them, which supports the body's own anti-tumor defenses.
Imjudo is designed for use with Imfinzi, and the two medicines work together in the STRIDE regimen. Each one targets a different checkpoint, so the combination gives the immune system support from two directions.
Imjudo is an approved option for unresectable liver cancer. In most plans it is given once, as a single priming dose over about 60 minutes. Treatment then continues with Imfinzi alone, and your care team monitors how you respond. Benefits vary from person to person.
Tell your care team right away if you have severe diarrhea, abdominal pain, jaundice, shortness of breath, or extreme fatigue. Your healthcare provider will discuss the potential benefits and risks before treatment and monitor you throughout.
SUPPORTING YOUR TREATMENT
Daily habits matter alongside Imjudo. Reporting symptoms early, staying hydrated, eating well, and keeping your scheduled oncology visits are all essential parts of treatment.
These habits help your care team catch immune-related side effects early and keep your treatment on track.
Areas that may support treatment:
common questions
Imjudo may suit people with unresectable hepatocellular carcinoma who are eligible for combination immunotherapy. Your provider may recommend it as part of the STRIDE regimen if your cancer needs systemic treatment and you may benefit from a stronger immune response against it. Eligibility depends on your diagnosis, overall health, and treatment goals. Only a qualified healthcare professional can decide whether Imjudo fits your situation, so talk with your liver or cancer specialist about your options.
No, Imjudo is not used on its own for liver cancer. It is given with Imfinzi (durvalumab) as part of the STRIDE regimen. Imjudo blocks the CTLA-4 checkpoint, while Imfinzi blocks a different checkpoint, PD-L1. Together, the two medicines work to help the immune system recognize and respond to cancer cells. Your healthcare provider will explain how the combination fits your care plan and what to expect at each visit.
A healthcare professional gives Imjudo by intravenous (IV) infusion, which takes about 60 minutes. You do not prepare or store it yourself. In the STRIDE regimen, Imjudo is given on Day 1. If you receive Imfinzi on the same day, Imjudo is infused first. Your care team sets the exact plan, so ask them what to expect on infusion day.
In most STRIDE plans, Imjudo is a single priming dose, so you receive it once. Treatment then continues with Imfinzi alone every 4 weeks until the disease progresses or side effects become unacceptable. Total treatment time depends on your response, how well you tolerate it, and the course of your disease. It may last months to years. Your healthcare provider will review your progress with you regularly.
Imjudo is an approved treatment option for unresectable hepatocellular carcinoma when it is used with Imfinzi. It blocks CTLA-4 to strengthen T-cell activity and boost the immune response against cancer. How well it works varies from person to person, and your care team checks your response at regular visits. Ask your healthcare provider what benefits you can reasonably expect, given your diagnosis and treatment goals.
Common side effects of Imjudo include fatigue, rash or itching, diarrhea, and decreased appetite. Because Imjudo activates the immune system, it can also cause immune-related inflammation in organs such as the liver, lungs, intestines, or endocrine glands. Your care team monitors you for these effects throughout treatment. Talk with your healthcare provider about the possible benefits and risks before you start.
Contact your care team promptly if you have severe diarrhea, abdominal pain, jaundice, shortness of breath, or extreme fatigue. These symptoms may point to immune-related side effects, so do not wait for your next appointment. Keep all scheduled oncology visits, stay hydrated, and maintain good nutrition. Your healthcare provider can decide whether you need an evaluation or a change to your treatment.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
